• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

    22.72 -0.35 (-1.52%)
    Streaming Delayed Price Updated: 2:41 PM EDT, Jul 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,271,009
    Open 23.07
    Bid (Size) 22.70 (400)
    Ask (Size) 22.75 (200)
    Prev. Close 23.07
    Today's Range 22.41 - 23.32
    52wk Range 8.060 - 25.00
    Shares Outstanding 58,310,703
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? ↗
    Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, and industry partnerships. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026? ↗
    Dyne pursues rare disease breakthroughs while Vertex leverages blockbuster profits for pipeline expansion, how do their risk profiles and financials compare? 
    Via The Motley Fool

    Performance

    YTD
    +22.8%
    +22.8%
    1 Month
    +33.3%
    +33.3%
    3 Month
    +23.8%
    +23.8%
    6 Month
    +24.6%
    +24.6%
    1 Year
    +177.8%
    +177.8%

    More News

    Read More
    News headline image
    Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
    Via The Motley Fool
    Dyne Therapeutics Inc (NASDAQ:DYN) Reports Narrower-Than-Expected Q4 2025 Loss, Reaffirms Key Clinical Timelines ↗
    Via Chartmill
    News headline image
    Dyne Therapeutics Appoints Barry Greene to Board of Directors
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
    Via The Motley Fool
    News headline image
    Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
    Via The Motley Fool
    News headline image
    Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Dyne Therapeutics to Participate in Upcoming Investor Conferences
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This Biotech Was Quietly Bought Before a $58 Per Share Takeout ↗
    Via The Motley Fool
    News headline image
    Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics to Participate in Upcoming Investor Conferences
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Dyne Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Dyne Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Dyne Therapeutics, Inc. - Common Stock trade on?
    Dyne Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Dyne Therapeutics, Inc. - Common Stock?
    The ticker symbol for Dyne Therapeutics, Inc. - Common Stock is DYN on the Nasdaq Stock Market
    What is the current price of Dyne Therapeutics, Inc. - Common Stock?
    The current price of Dyne Therapeutics, Inc. - Common Stock is 22.72
    When was Dyne Therapeutics, Inc. - Common Stock last traded?
    The last trade of Dyne Therapeutics, Inc. - Common Stock was at 07/06/26 02:41 PM ET
    What is the market capitalization of Dyne Therapeutics, Inc. - Common Stock?
    The market capitalization of Dyne Therapeutics, Inc. - Common Stock is 1.32B
    How many shares of Dyne Therapeutics, Inc. - Common Stock are outstanding?
    Dyne Therapeutics, Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.